title: Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
abstract: We assessed the broadly used, off-label combination of sofosbuvir, daclatasvir, simeprevir, and ribavirin in direct-acting antiviral-experienced patients, as recommended in current guidelines despite scarce data. After 24 weeks' treatment, sustained virological response 12 weeks after the end of treatment was achieved in 6 patients (60%). Two cirrhotic patients relapsed and 2 discontinued treatment due to serious adverse events.
authors.affiliation: Department of Hepatology and.|INSERM U955, Créteil, France.
authors.forename: Christophe
authors.initials: C
authors.lastname: Hézode
authors.affiliation: National Reference Center for Viral Hepatitis B, C and Delta, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, and.|INSERM U955, Créteil, France.
authors.forename: Slim
authors.initials: S
authors.lastname: Fourati
authors.affiliation: National Reference Center for Viral Hepatitis B, C and Delta, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, and.|INSERM U955, Créteil, France.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Chevaliez
authors.affiliation: Department of Hepatology and.
authors.forename: Giovanna
authors.initials: G
authors.lastname: Scoazec
authors.affiliation: National Reference Center for Viral Hepatitis B, C and Delta, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, and.|INSERM U955, Créteil, France.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Soulier
authors.affiliation: Department of Hepatology and.
authors.forename: Anne
authors.initials: A
authors.lastname: Varaut
authors.affiliation: Department of Hepatology and.
authors.forename: Murielle
authors.initials: M
authors.lastname: François
authors.affiliation: Department of Hepatology and.|National Reference Center for Viral Hepatitis B, C and Delta, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, and.|INSERM U955, Créteil, France.
authors.forename: Isaac
authors.initials: I
authors.lastname: Ruiz
authors.affiliation: Department of Hepatology and.
authors.forename: Françoise
authors.initials: F
authors.lastname: Roudot-Thoraval
authors.affiliation: Department of Hepatology and.|INSERM U955, Créteil, France.
authors.forename: Ariane
authors.initials: A
authors.lastname: Mallat
authors.affiliation: National Reference Center for Viral Hepatitis B, C and Delta, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, and.|INSERM U955, Créteil, France.
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Pawlotsky
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002219:Carbamates; D024882:Drug Resistance, Viral / Q000235:genetics; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011759:Pyrrolidines; D012008:Recurrence; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000069616:Simeprevir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000069474:Sofosbuvir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000072230:Sustained Virologic Response; D014633:Valine / Q000031:analogs & derivatives
chemical_list: D000998:Antiviral Agents; D002219:Carbamates; D007093:Imidazoles; D011759:Pyrrolidines; D012254:Ribavirin; D000069616:Simeprevir; D014633:Valine; C549273:daclatasvir; D000069474:Sofosbuvir
keywords: chronic hepatitis C; resistance; resistance-associated substitutions.; retreatment; sustained virological response